Publications

  1. Yamanaka S. (2024) Shinya Yamanaka Q & A. Cell 187:(13) 3229-3230 PMID: 38906098
  2. Kunitomi A, Hirohata R, Osawa M, Washizu K, Arreola V, Saiki N, Kato TM, Nomura M, Kunitomi H, Ohkame T, Ohkame Y, Kawaguchi J, Hara H, Kusano K, Yamamoto T, Takashima Y, Tohyama S, Yuasa S, Fukuda K, Takasu N, and Yamanaka S. (2024) H1foo-Dd Promotes Efficiency and Uniformity in Reprogramming to Naive Pluripotency. Stem Cell Rep 19:(5) 710–728 PMC11103934
  3. Hui KK and Yamanaka S. (2024) Ips Cell Therapy 2.0: Preparing for Next-Generation Regenerative Medicine. Bioessays PMID: 38922935
  4. Yoshida S, Kato TM, Sato Y, Umekage M, Ichisaka T, Tsukahara M, Takasu N, and Yamanaka S. (2023) A Clinical-Grade Hla Haplobank of Human Induced Pluripotent Stem Cells Matching Approximately 40% of the Japanese Population. Med 4:(1) 51-66.e10 PMID: 36395757
  5. Vasic I, Libby ARG, Maslan A, Bulger EA, Zalazar D, Krakora Compagno MZ, Streets A, Tomoda K, Yamanaka S, and McDevitt TC. (2023) Loss of Tjp1 Disrupts Gastrulation Patterning and Increases Differentiation toward the Germ Cell Lineage in Human Pluripotent Stem Cells. Dev Cell 58:(16) 1477-1488.e1475 PMC10529434
  6. Takayama K and Yamanaka S. (2023) Pluripotent Stem Cell-Based Therapies and Their Path to the Clinic. Stem Cell Reports 18:(8) 1547-1548 PMC10444574
  7. Saito MK, Osawa M, Tsuchida N, Shiraishi K, Niwa A, Woltjen K, Asaka I, Ogata K, Ito S, Kobayashi S, and Yamanaka S. (2023) A Disease-Specific Ips Cell Resource for Studying Rare and Intractable Diseases. Inflammation and Regeneration 43:(1) PMC10485998
  8. Takahashi K, Okubo C, Nakamura M, Iwasaki M, Kawahara Y, Tabata T, Miyamoto Y, Woltjen K, and Yamanaka S. (2022) A Stress-Reduced Passaging Technique Improves the Viability of Human Pluripotent Cells. Cell Rep Methods 2:(2) 100155 PMC9017214
  9. Suzuki T, Aizawa K, Shibuya K, Yamanaka S, Anzai Y, Kurokawa K, and Nagai R. (2022) Prevalence of Asymptomatic Sars-Cov-2 Infection in Japan. JAMA Netw Open 5:(12) e2247704 PMC9856923
  10. Kunitomi A, Hirohata R, Arreola V, Osawa M, Kato TM, Nomura M, Kawaguchi J, Hara H, Kusano K, Takashima Y, Takahashi K, Fukuda K, Takasu N, and Yamanaka S. (2022) Improved Sendai Viral System for Reprogramming to Naive Pluripotency. Cell Rep Methods 2:(11) 100317 PMC9701587
  11. Iwasaki M, Kawahara Y, Okubo C, Yamakawa T, Nakamura M, Tabata T, Nishi Y, Narita M, Ohta A, Saito H, Yamamoto T, Nakagawa M, Yamanaka S, and Takahashi K. (2022) Multi-Omics Approach Reveals Posttranscriptionally Regulated Genes Are Essential for Human Pluripotent Stem Cells. iScience 25:(5) 104289 PMC9097716
  12. Takahashi K, Nakamura M, Okubo C, Kliesmete Z, Ohnuki M, Narita M, Watanabe A, Ueda M, Takashima Y, Hellmann I, and Yamanaka S. (2021) The Pluripotent Stem Cell-Specific Transcript Esrg Is Dispensable for Human Pluripotency. PLoS Genet 17:(5) e1009587 PMC8184003
  13. Sugai K, Sumida M, Shofuda T, Yamaguchi R, Tamura T, Kohzuki T, Abe T, Shibata R, Kamata Y, Ito S, Okubo T, Tsuji O, Nori S, Nagoshi N, Yamanaka S, Kawamata S, Kanemura Y, Nakamura M, and Okano H. (2021) First-in-Human Clinical Trial of Transplantation of Ipsc-Derived Ns/Pcs in Subacute Complete Spinal Cord Injury: Study Protocol. Regen Ther 18:(321-333 PMC8427225
  14. Okubo C, Narita M, Inagaki A, Nishikawa M, Hotta A, Yamanaka S, and Yoshida Y. (2021) Expression Dynamics of Hand1/2 in in Vitro Human Cardiomyocyte Differentiation. Stem Cell Reports 16:(8) 1906-1922 PMC8365100
  15. Karagiannis P and Yamanaka S. (2021) Konnichiwa: Japanese Scientists and Their Struggle to Speak English: More Research Careers in Japan Need Less English. EMBO Rep 22:(4) e52558 PMC8024886
  16. Jo N, Zhang R, Ueno H, Yamamoto T, Weiskopf D, Nagao M, Yamanaka S, and Hamazaki Y. (2021) Aging and Cmv Infection Affect Pre-Existing Sars-Cov-2-Reactive Cd8(+) T Cells in Unexposed Individuals. Front Aging 2:(719342 PMC9261342
  17. Hashimoto R, Sakamoto A, Deguchi S, Yi R, Sano E, Hotta A, Takahashi K, Yamanaka S, and Takayama K. (2021) Dual Inhibition of Tmprss2 and Cathepsin Bprevents Sars-Cov-2 Infection in Ips Cells. Mol Ther Nucleic Acids 26:(1107-1114 PMC8527102
  18. Yamanaka S. (2020) Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Cell Stem Cell 27:(4) 523-531 
  19. Takahashi K, Jeong D, Wang S, Narita M, Jin X, Iwasaki M, Perli SD, Conklin BR, and Yamanaka S. (2020) Critical Roles of Translation Initiation and Rna Uridylation in Endogenous Retroviral Expression and Neural Differentiation in Pluripotent Stem Cells. Cell Rep 31:(9) 107715 PMC8195978
  20. Wu JC, Garg P, Yoshida Y, Yamanaka S, Gepstein L, Hulot JS, Knollmann BC, and Schwartz PJ. (2019) Towards Precision Medicine with Human Ipscs for Cardiac Channelopathies. Circ Res 125:(6) 653-658 PMC10765953
  21. Tsuji O, Sugai K, Yamaguchi R, Tashiro S, Nagoshi N, Kohyama J, Iida T, Ohkubo T, Itakura G, Isoda M, Shinozaki M, Fujiyoshi K, Kanemura Y, Yamanaka S, Nakamura M, and Okano H. (2019) Concise Review: Laying the Groundwork for a First-in-Human Study of an Induced Pluripotent Stem Cell-Based Intervention for Spinal Cord Injury. Stem Cells 37:(1) 6-13 PMC7379555
  22. Suga M, Kondo T, Imamura K, Shibukawa R, Okanishi Y, Sagara Y, Tsukita K, Enami T, Furujo M, Saijo K, Nakamura Y, Osawa M, Saito MK, Yamanaka S, and Inoue H. (2019) Generation of a Human Induced Pluripotent Stem Cell Line, Brci001-a, Derived from a Patient with Mucopolysaccharidosis Type I. Stem Cell Res 36:(101406 
  23. Kime C, Kiyonari H, Ohtsuka S, Kohbayashi E, Asahi M, Yamanaka S, Takahashi M, and Tomoda K. (2019) Induced 2c Expression and Implantation-Competent Blastocyst-Like Cysts from Primed Pluripotent Stem Cells. Stem Cell Reports 13:(3) 485-498 PMC6739768
  24. Karagiannis P, Yamanaka S, and Saito MK. (2019) Application of Induced Pluripotent Stem Cells to Primary Immunodeficiency Diseases. Exp Hematol 71:(43-50 
  25. Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita JK, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, and Osafune K. (2019) Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development. Physiol Rev 99:(1) 79-114 
  26. Karagiannis P, Nakauchi A, and Yamanaka S. (2019) Erratum for Doi: 10.31662/Jmaj.2018-0005. JMA J 2:(1) 101 PMC7930714
  27. Araki H, Miura F, Watanabe A, Morinaga C, Kitaoka F, Kitano Y, Sakai N, Shibata Y, Terada M, Goto S, Yamanaka S, Takahashi M, and Ito T. (2019) Base-Resolution Methylome of Retinal Pigment Epithelial Cells Used in the First Trial of Human Induced Pluripotent Stem Cell-Based Autologous Transplantation. Stem Cell Rep 13:(4) 761-774 6829753
  28. Rand TA, Sutou K, Tanabe K, Jeong D, Nomura M, Kitaoka F, Tomoda E, Narita M, Nakamura M, Nakamura M, Watanabe A, Rulifson E, Yamanaka S, and Takahashi K. (2018) Myc Releases Early Reprogrammed Human Cells from Proliferation Pause Via Retinoblastoma Protein Inhibition. Cell Rep 23:(2) 361-375 
  29. Karagiannis P, Nakauchi A, and Yamanaka S. (2018) Bringing Induced Pluripotent Stem Cell Technology to the Bedside. JMA J 1:(1) 6-14 PMC7969850
  30. International Stem Cell I. (2018) Assessment of Established Techniques to Determine Developmental and Malignant Potential of Human Pluripotent Stem Cells. Nat Commun 9:(1) 1925 PMC5954055
  31. Yoshida Y and Yamanaka S. (2017) Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. Circ Res 120:(12) 1958-1968 
  32. Yagi M, Yamanaka S, and Yamada Y. (2017) Epigenetic Foundations of Pluripotent Stem Cells That Recapitulate in Vivo Pluripotency. Lab Invest 97:(10) 1133-1141 
  33. Sugiyama H, Takahashi K, Yamamoto T, Iwasaki M, Narita M, Nakamura M, Rand TA, Nakagawa M, Watanabe A, and Yamanaka S. (2017) Nat1 Promotes Translation of Specific Proteins That Induce Differentiation of Mouse Embryonic Stem Cells. Proc Natl Acad Sci U S A 114:(2) 340-345 5240712
  34. Sone M, Morone N, Nakamura T, Tanaka A, Okita K, Woltjen K, Nakagawa M, Heuser JE, Yamada Y, Yamanaka S, and Yamamoto T. (2017) Hybrid Cellular Metabolism Coordinated by Zic3 and Esrrb Synergistically Enhances Induction of Naive Pluripotency. Cell Metab 25:(5) 1103-1117 e1106 
  35. Shi Y, Inoue H, Wu JC, and Yamanaka S. (2017) Induced Pluripotent Stem Cell Technology: A Decade of Progress. Nat Rev Drug Discov 16:(2) 115-130 PMC6416143
  36. Parr CJC, Yamanaka S, and Saito H. (2017) An Update on Stem Cell Biology and Engineering for Brain Development. Mol Psychiatry 22:(6) 808-819 PMID: 28373686
  37. Morizane A, Kikuchi T, Hayashi T, Mizuma H, Takara S, Doi H, Mawatari A, Glasser MF, Shiina T, Ishigaki H, Itoh Y, Okita K, Yamasaki E, Doi D, Onoe H, Ogasawara K, Yamanaka S, and Takahashi J. (2017) Mhc Matching Improves Engraftment of Ipsc-Derived Neurons in Non-Human Primates. Nat Commun 8:(1) 385 PMC5577234
  38. Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, Fujihara M, Akimaru H, Sakai N, Shibata Y, Terada M, Nomiya Y, Tanishima S, Nakamura M, Kamao H, Sugita S, Onishi A, Ito T, Fujita K, Kawamata S, Go MJ, Shinohara C, Hata KI, Sawada M, Yamamoto M, Ohta S, Ohara Y, Yoshida K, Kuwahara J, Kitano Y, Amano N, Umekage M, Kitaoka F, Tanaka A, Okada C, Takasu N, Ogawa S, Yamanaka S, and Takahashi M. (2017) Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N Engl J Med 376:(11) 1038-1046 
  39. Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Funakoshi S, Yoshida Y, Yamanaka S, Shimizu T, Okano T, Daimon T, Toda K, and Sawa Y. (2017) Enhanced Therapeutic Effects of Human Ips Cell Derived-Cardiomyocyte by Combined Cell-Sheets with Omental Flap Technique in Porcine Ischemic Cardiomyopathy Model. Sci Rep 7:(1) 8824 PMC5562896
  40. Karagiannis P, Onodera A, and Yamanaka S. (2017) New Models for Therapeutic Innovation from Japan. EBioMedicine 18:(3-4 PMC5405189
  41. Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo T, Kitaoka S, Ohta A, Tanaka A, Watanabe D, Morita M, Takuma H, Tamaoka A, Kunath T, Wray S, Furuya H, Era T, Makioka K, Okamoto K, Fujisawa T, Nishitoh H, Homma K, Ichijo H, Julien JP, Obata N, Hosokawa M, Akiyama H, Kaneko S, Ayaki T, Ito H, Kaji R, Takahashi R, Yamanaka S, and Inoue H. (2017) The Src/C-Abl Pathway Is a Potential Therapeutic Target in Amyotrophic Lateral Sclerosis. Sci Transl Med 9:(391) 
  42. Ikeda H, Sone M, Yamanaka S, and Yamamoto T. (2017) Structural and Spatial Chromatin Features at Developmental Gene Loci in Human Pluripotent Stem Cells Nat Commun 8:(1) 1616 5696376
  43. Yoshida Y and Yamanaka S. (2016) Understanding Intracellular Signaling Advances Cardiac Reprogramming Technology toward Clinical Applications. Circ Res 118:(3) 377-378 
  44. Yamakawa T, Sato Y, Matsumura Y, Kobayashi Y, Kawamura Y, Goshima N, Yamanaka S, and Okita K. (2016) Screening of Human Cdna Library Reveals Two Differentiation-Related Genes, Hhex and Hlx, as Promoters of Early Phase Reprogramming toward Pluripotency. Stem Cells 34:(11) 2661-2669 
  45. Takahashi K and Yamanaka S. (2016) A Decade of Transcription Factor-Mediated Reprogramming to Pluripotency. Nat Rev Mol Cell Biol 17:(3) 183-193 
  46. Sasaki K, Makiyama T, Yoshida Y, Wuriyanghai Y, Kamakura T, Nishiuchi S, Hayano M, Harita T, Yamamoto Y, Kohjitani H, Hirose S, Chen J, Kawamura M, Ohno S, Itoh H, Takeuchi A, Matsuoka S, Miura M, Sumitomo N, Horie M, Yamanaka S, and Kimura T. (2016) Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia. PLoS One 11:(10) e0164795 PMC5072719
  47. Parr CJ, Katayama S, Miki K, Kuang Y, Yoshida Y, Morizane A, Takahashi J, Yamanaka S, and Saito H. (2016) Microrna-302 Switch to Identify and Eliminate Undifferentiated Human Pluripotent Stem Cells. Sci Rep 6:(32532 PMC5016789
  48. Panula S, Reda A, Stukenborg JB, Ramathal C, Sukhwani M, Albalushi H, Edsgard D, Nakamura M, Soder O, Orwig KE, Yamanaka S, Reijo Pera RA, and Hovatta O. (2016) Over Expression of Nanos3 and Dazl in Human Embryonic Stem Cells. PLoS One 11:(10) e0165268 PMC5074499
  49. Nishizawa M, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A, Nishikawa M, Takei I, Oishi A, Tanabe K, Ohnuki M, Yokota H, Koyanagi-Aoi M, Okita K, Watanabe A, Takaori-Kondo A, Yamanaka S, and Yoshida Y. (2016) Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Cell Stem Cell 19:(3) 341-354 
  50. Nakagawa M, Karagiannis P, and Yamanaka S. (2016) When Myc's Asleep, Embryonic Stem Cells Are Dormant. EMBO J 35:(8) 801-802 PMC4972139
  51. Myers SA, Peddada S, Chatterjee N, Friedrich T, Tomoda K, Krings G, Thomas S, Maynard J, Broeker M, Thomson M, Pollard K, Yamanaka S, Burlingame AL, and Panning B. (2016) Sox2 O-Glcnacylation Alters Its Protein-Protein Interactions and Genomic Occupancy to Modulate Gene Expression in Pluripotent Cells. Elife 5:(e10647 PMC4841768
  52. Kime C, Sakaki-Yumoto M, Goodrich L, Hayashi Y, Sami S, Derynck R, Asahi M, Panning B, Yamanaka S, and Tomoda K. (2016) Autotaxin-Mediated Lipid Signaling Intersects with Lif and Bmp Signaling to Promote the Naive Pluripotency Transcription Factor Program. Proc Natl Acad Sci U S A 113:(44) 12478-12483 PMC5098653
  53. Kime C, Mandegar MA, Srivastava D, Yamanaka S, Conklin BR, and Rand TA. (2016) Efficient Crispr/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells. Curr Protoc Hum Genet 88:(21 24 21-21 24 23 PMC4726454
  54. Kim SI, Oceguera-Yanez F, Sakurai C, Nakagawa M, Yamanaka S, and Woltjen K. (2016) Inducible Transgene Expression in Human Ips Cells Using Versatile All-in-One Piggybac Transposons. Methods Mol Biol 1357:(111-131 
  55. Hayashi Y, Hsiao EC, Sami S, Lancero M, Schlieve CR, Nguyen T, Yano K, Nagahashi A, Ikeya M, Matsumoto Y, Nishimura K, Fukuda A, Hisatake K, Tomoda K, Asaka I, Toguchida J, Conklin BR, and Yamanaka S. (2016) Bmp-Smad-Id Promotes Reprogramming to Pluripotency by Inhibiting P16/Ink4a-Dependent Senescence. Proc Natl Acad Sci U S A 113:(46) 13057-13062 PMC5135304
  56. Funakoshi S, Miki K, Takaki T, Okubo C, Hatani T, Chonabayashi K, Nishikawa M, Takei I, Oishi A, Narita M, Hoshijima M, Kimura T, Yamanaka S, and Yoshida Y. (2016) Enhanced Engraftment, Proliferation, and Therapeutic Potential in Heart Using Optimized Human Ipsc-Derived Cardiomyocytes. Sci Rep 6:(19111 PMC4705488
  57. Fukusumi H, Shofuda T, Bamba Y, Yamamoto A, Kanematsu D, Handa Y, Okita K, Nakamura M, Yamanaka S, Okano H, and Kanemura Y. (2016) Establishment of Human Neural Progenitor Cells from Human Induced Pluripotent Stem Cells with Diverse Tissue Origins. Stem Cells Int 2016:(7235757 PMC4861799
  58. Azuma K and Yamanaka S. (2016) Recent Policies That Support Clinical Application of Induced Pluripotent Stem Cell-Based Regenerative Therapies. Regen Ther 4:(36-47 PMC6581825
  59. Ameku T, Taura D, Sone M, Numata T, Nakamura M, Shiota F, Toyoda T, Matsui S, Araoka T, Yasuno T, Mae S, Kobayashi H, Kondo N, Kitaoka F, Amano N, Arai S, Ichisaka T, Matsuura N, Inoue S, Yamamoto T, Takahashi K, Asaka I, Yamada Y, Ubara Y, Muso E, Fukatsu A, Watanabe A, Sato Y, Nakahata T, Mori Y, Koizumi A, Nakao K, Yamanaka S, and Osafune K. (2016) Identification of Mmp1 as a Novel Risk Factor for Intracranial Aneurysms in Adpkd Using Ipsc Models. Sci Rep 6:(30013 PMC4945931